ES2290046T3 - Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. - Google Patents

Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. Download PDF

Info

Publication number
ES2290046T3
ES2290046T3 ES00944977T ES00944977T ES2290046T3 ES 2290046 T3 ES2290046 T3 ES 2290046T3 ES 00944977 T ES00944977 T ES 00944977T ES 00944977 T ES00944977 T ES 00944977T ES 2290046 T3 ES2290046 T3 ES 2290046T3
Authority
ES
Spain
Prior art keywords
profile data
calibrated
panel
sample
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00944977T
Other languages
English (en)
Spanish (es)
Inventor
Victor Tryon
Michael P. Bevilacqua
Danute M. Bankaitis-Davis
John Cheronis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Source Precision Medicine Inc
Original Assignee
Source Precision Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26839213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2290046(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Source Precision Medicine Inc filed Critical Source Precision Medicine Inc
Application granted granted Critical
Publication of ES2290046T3 publication Critical patent/ES2290046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES00944977T 1999-06-28 2000-06-28 Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica. Expired - Lifetime ES2290046T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14154299P 1999-06-28 1999-06-28
US141542P 1999-06-28
US19552200P 2000-04-07 2000-04-07
US195522P 2000-04-07

Publications (1)

Publication Number Publication Date
ES2290046T3 true ES2290046T3 (es) 2008-02-16

Family

ID=26839213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00944977T Expired - Lifetime ES2290046T3 (es) 1999-06-28 2000-06-28 Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica.

Country Status (13)

Country Link
EP (1) EP1198585B1 (https=)
JP (1) JP2004528526A (https=)
KR (1) KR20020079364A (https=)
AT (1) ATE364721T1 (https=)
AU (1) AU784233B2 (https=)
CA (1) CA2378008A1 (https=)
CY (1) CY1107733T1 (https=)
DE (1) DE60035196T2 (https=)
DK (1) DK1198585T3 (https=)
ES (1) ES2290046T3 (https=)
IL (2) IL147349A0 (https=)
PT (1) PT1198585E (https=)
WO (1) WO2001025473A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
AUPR480901A0 (en) * 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
EP1392871A4 (en) * 2001-05-22 2006-04-19 Gene Logic Inc MODELING MOLECULAR TOXICITY
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2277991A1 (en) * 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
JP4632788B2 (ja) 2002-09-20 2011-02-16 ニュー・イングランド・バイオラブズ・インコーポレイティッド 核酸のヘリカーゼ依存性増幅
AU2002952696A0 (en) * 2002-11-14 2002-11-28 Genomics Research Partners Pty Ltd Status determination
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
AU2003901196A0 (en) * 2003-03-17 2003-04-03 Commonwealth Scientific And Industrial Research Organisation Analysis method
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
JPWO2005087924A1 (ja) * 2004-02-18 2008-01-31 株式会社三重ティーエルオー Dnaチップ並びに疾患関連遺伝子の抽出方法
EP2062981B1 (en) 2005-06-16 2013-09-25 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
AU2007254206A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2315858A2 (en) 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
NZ593854A (en) 2009-01-06 2013-02-22 Source Prec Medicine Inc D B A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
US9074248B1 (en) 2012-12-18 2015-07-07 Qiagen Gmbh Primers for helicase dependent amplification and their methods of use
CN103525926B (zh) * 2013-10-08 2016-03-23 浙江大学 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5922184A (en) * 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
EP0960214A4 (en) * 1996-12-06 2004-08-04 Urocor Inc Diagnosis of disease status on HAnd from mRNA profiles
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
WO1999011822A1 (en) * 1997-09-03 1999-03-11 Gene Logic Inc. Method for predicting prognosis and treatment response for genetically based abnormalities
US6461817B1 (en) * 1997-09-12 2002-10-08 The Public Health Research Institute Of The City Of New York Non-competitive co-amplification methods
EP1027456B1 (en) * 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs

Also Published As

Publication number Publication date
EP1198585B1 (en) 2007-06-13
AU784233B2 (en) 2006-02-23
ATE364721T1 (de) 2007-07-15
AU5898500A (en) 2001-05-10
DK1198585T3 (da) 2007-10-15
JP2004528526A (ja) 2004-09-16
DE60035196T2 (de) 2008-02-21
KR20020079364A (ko) 2002-10-19
CY1107733T1 (el) 2013-04-18
PT1198585E (pt) 2007-09-20
IL147349A0 (en) 2002-08-14
EP1198585A1 (en) 2002-04-24
WO2001025473A9 (en) 2002-08-08
IL147349A (en) 2011-12-29
DE60035196D1 (de) 2007-07-26
CA2378008A1 (en) 2001-04-12
WO2001025473A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
ES2290046T3 (es) Procedimiento para caracterizar un estado biologico, mediante el empleo de perfiles calibrados de expresion genica.
Wienke Frailty models in survival analysis
Slonim et al. Getting started in gene expression microarray analysis
EP1451340A1 (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20040219568A1 (en) Systems and methods for characterizing a biological conditions or agent using selected gene expression profiles
Shaffer et al. A comparison of DNA/RNA extraction protocols for high-throughput sequencing of microbial communities
EP2066809A2 (en) Gene expression profiling for identification, monitoring and treatment of transplant rejection
JP2010227111A (ja) 遺伝子発現プロフィールを用いる、感染症の同定、モニタリング、および処置、ならびに感染症に関連する炎症状態の特徴付け
JP2005508505A5 (https=)
JP7141029B2 (ja) データベースを構築する方法
Mistry et al. Ventricular-subventricular zone contact by glioblastoma is not associated with molecular signatures in bulk tumor data
WO2009158513A1 (en) Gene expression profiling for identification, monitoring, and treatment of osteoarthritis
AU2003303238A2 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
JP2006510382A5 (https=)
Sutherland et al. Canadian lung tissue biobank with associated clinical data supporting respiratory research for four decades
Xunlu et al. Integrative bioinformatics analysis reveals potential gene biomarkers and analysis of function in human degenerative disc annulus fibrosus cells
North The global alliance for genomics and health: towards international sharing of genomic and clinical data
Marine et al. Cell position matters in tumour development
Zapotocky et al. Gene-14. Unique molecular and clinical features of Li-Fraumeni syndrome associated brain tumours
Chowdhury et al. Protein-Protein Interaction Network and Novel Biomarkers of Celiac Disease
Karvonen et al. GENE-17. Tumor-derived cell-free DNA may be frequently detected by clinical targeted sequencing of cerebrospinal fluid in children with brain tumors
Eriksen What are the Prospects for-Omics-Based Molecular Technologies in Cancer Diagnostics and Treatment
Xu et al. Pathway cross-talk analysis in detecting significant pathways in Barrett’s esophagus patients
HK1169190A (en) Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
Dolci et al. P255 Avascular osteonecrosis of the jawbones in oncological patients related to the use of bisphophonates: the role of a correct diagnosis as the first step of the treatement planning